Musto P - Search Results

1

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.

Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias. Musto P, et al. Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894. Cancer. 2010. PMID: 20151429 Free article.

2

Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.

Musto P, Matera R, Minervini MM, Checchia-de Ambrosio C, Bodenizza C, Falcone A, Carotenuto M. Musto P, et al. Haematologica. 1994 May-Jun;79(3):265-8. Haematologica. 1994. PMID: 7926977 Clinical Trial.

3

Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.

Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M. Musto P, et al. Haematologica. 2001 Jan;86(1):44-51. Haematologica. 2001. PMID: 11146570

4

Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.

Grossi A, Musto P, Santini V, Balestri F, Fabbri A, Falcone A, Sanpaolo G. Grossi A, et al. Among authors: musto p. Haematologica. 2002 Mar;87(3):322-3. Haematologica. 2002. PMID: 11869946

5

Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes.

Musto P, Falcone A, Sanpaolo G, Bodenizza C, La Sala A, Perla G, Carella AM. Musto P, et al. Br J Haematol. 2003 Jul;122(2):269-71. doi: 10.1046/j.1365-2141.2003.04435.x. Br J Haematol. 2003. PMID: 12846896 Free article. Clinical Trial.

6

Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.

Musto P. Musto P. Leuk Res. 2004 Apr;28(4):325-32. doi: 10.1016/j.leukres.2003.08.007. Leuk Res. 2004. PMID: 15109529 Review.

7

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.

Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G, Bodenizza C, Scalzulli PR, La Sala A, Campioni D, Ghio R, Cascavilla N, Carella AM. Musto P, et al. Br J Haematol. 2005 Jan;128(2):204-9. doi: 10.1111/j.1365-2141.2004.05288.x. Br J Haematol. 2005. PMID: 15638854 Free article.

8

Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes.

Musto P. Musto P. Clin Lymphoma. 2005 Jun;6(1):52-5. doi: 10.3816/clm.2005.n.029. Clin Lymphoma. 2005. PMID: 15989709 Review. No abstract available.

9

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.

Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, Grasso M, Falco P, Cangialosi C, Boccadoro M. Palumbo A, et al. Among authors: musto p. Cancer. 2005 Oct 1;104(7):1428-33. doi: 10.1002/cncr.21342. Cancer. 2005. PMID: 16116606 Free article.

10

Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.

Musto P, Falcone A, Sanpaolo G, Bodenizza C. Musto P, et al. Leuk Res. 2006 Apr;30(4):385-8. doi: 10.1016/j.leukres.2005.08.020. Epub 2005 Oct 10. Leuk Res. 2006. PMID: 16219350 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

646 results

Search Page

Filters